Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 [gaboxadol] in Adult Patients With Primary Insomnia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 25 Aug 2008 New trial record.